A TROP2/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast CancerBogang Wu, Leif W. Ellisen, Ting Liu et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 5
Abstract PR08: Intratumoral heterogeneity drives resistance to Antibody Drug Conjugate therapy: Analysis of the NeoSTAR trial of neoadjuvant Sacituzumab govitecan for localized TNBCLaura M. Spring, Leif W. Ellisen, Bogang Wu et al.|Cancer Research|2024Cited by 2